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Starting patients on dialysis early has been increasing in
incidence in several countries. However, some studies have
questioned its utility, finding a counter-intuitive effect of
increased mortality when dialysis was started at a higher
estimated glomerular filtration rate (eGFR). To examine this
issue in more detail we measured mortality hazard ratios
associated with Modification of Diet in Renal Disease eGFR at
dialysis initiation for 11,685 patients from the French REIN
Registry, with sequential adjustment for a number of
covariates. The eGFR was analyzed both quantitatively by
5-ml/min per 1.73m2 increments and by demi-decile (i.e.,
5 percentiles of the distribution); the 15th demi-decile,
including values around 10ml/min per 1.73m2, was our
reference point. The patients more likely to begin dialysis at a
higher eGFR were older male patients; had diabetes,
cardiovascular diseases, or low body mass index and level of
albuminemia; or were started with peritoneal dialysis. During
a median follow-up of 21.9 months, 3945 patients died. The
2-year crude survival decreased from 79 to 46%, with
increasing eGFR from less than 5 to over 20ml/min per
1.73m2. Each 5-ml/min/1.73m2 increase in eGFR was
associated with a 40% increase in crude mortality risk, which
weakened to 9%, but remained statistically significant after
adjusting for the above covariates. Analysis by demi-decile
showed only the highest to be at significantly higher risk.
Hence we found that age and patient condition strongly
determine the decision to start dialysis and may explain most
of the inverse association between eGFR and survival.
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The optimal timing for starting dialysis in patients with end-
stage renal disease (ESRD) remains uncertain; the decision is
based mainly on clinical experience and local dialysis
resources.1,2 International guidelines are consistent in recom-
mending the initiation of dialysis whenever signs of uremia or
malnutrition are present, or when blood pressure or hydration
status cannot be controlled, but they differ regarding the level
of estimated glomerular filtration rate (eGFR) at which dialysis
should start in the absence of these conditions, ranging from 8
to 12ml/min per 1.73m2 according to country.3–6 One of the
recommendations is to consider starting dialysis at values of
renal function equal to a Kt/V of 2.0 equivalent to an eGFR of
about 10.5ml/min.3 All agree, however, that it should certainly
be started once eGFR reaches 5–6ml/min per 1.73m2.
The so-called healthy start concept, which recommended
that dialysis start before overt evidence of uremia, was based on
early studies that reported a higher mortality risk with low
eGFR at initiation7 and led to the start of dialysis at higher
eGFR levels.8,9 In the United States,2 the percentage of patients
starting dialysis with eGFR greater than 10ml/min per 1.73m2
more than doubled between 1996 and 2005, from 25 to 54%,
whereas in France it has been stable at 30% since the beginning
of the Renal Epidemiology and Information Network (REIN)
Registry in 2002. The Netherlands Cooperative Study on the
Adequacy of Dialysis (NECOSAD) study, however, showed that
the apparent gain in survival in these observational studies
is more likely to have resulted from lead-time bias than
from true effects of an early start.10 In contrast, more recent
studies tend to show decrease of survival with higher GFRs
at initiation, an inverse association that appeared to be only
partly explained by comorbidity.11–16 It is important to
clarify whether this reflects a potentially harmful effect of
early dialysis, indication bias, or confounding from comorbid
conditions. Randomized clinical trials are theoretically the
most appropriate way to investigate this issue, but the
importance of observational studies in evaluating treatment
options is increasingly being recognized, particularly those
based on large unselected ESRD registry populations.17
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We, therefore, investigated the association between eGFR
level at dialysis initiation and mortality risk in the French
REIN Registry, adjusting for a large set of potential
explanatory variables and testing for interactions with patient
characteristics and treatment conditions.
RESULTS
Distribution of eGFR at start of dialysis
The mean (s.d.) and median (interquartile range) Modifica-
tion of Diet in Renal Disease (MDRD) eGFR values were 8.8
(4.1) and 7.9 (5.9–10.6) ml/min per 1.73m2, respectively;
overall values ranged from 0.7 to 35.2ml/min per 1.73m2
(Figure 1). Fourteen percent of the patients started dialysis
with eGFRp5 and 8% with eGFR415ml/min per 1.73m2.
Baseline patient characteristics and initial dialysis
conditions according to eGFR
As MDRD eGFR at start of dialysis increased, patient age and
percentage of men also increased significantly, and patients
were more likely to have diabetes, vascular nephropathy,
malignancy, and cardiovascular diseases, as well as reduced
mobility and lower body mass index (BMI) and albuminemia
level, independent of age and gender (Table 1). The
proportion of those with an eGFR 410ml/min per 1.73m2
was nearly three times higher in the oldest than in the
youngest age group (Figure 2). Patients with lower eGFR
were more likely to have low hemoglobin levels and to have
received predialysis erythropoiesis-stimulating agent treat-
ment. The level of eGFR was not related to history of stroke,
liver disease, or chronic respiratory disease, or to smoking or
severe disability. Higher the eGFR, higher the percentage of
patients starting with planned peritoneal dialysis. There was a
U-shaped relation between the percentage of patients with
unplanned dialysis and eGFR level. In all, the above
significant variables explained 17.5% of the variance of
MDRD eGFR treated continuously.
The duration of weekly hemodialysis (HD) decreased and
the percentage of patients treated with fewer than three
sessions per week increased with increasing eGFR up to 20ml/
min per 1.73m2 (Table 2). Patients with eGFR 420ml/
min per 1.73m2 were more likely to start with more than
three sessions per week. All patients (n¼ 14) with more than
three sessions began on emergency; 9 (64%) had stage-3–4
heart failure and 11 (79%) received shorter sessions, o4 h
per session.
Patient survival and transplantation according
to MDRD-estimated GFR
Over a median follow-up of 21.9 months, 3945 patients died.
Survival decreased strongly with increasing MDRD eGFR
(Figure 3, log rank Po0.0001). Two-year survival decreased
from 79 to 46% for the lowest versus the highest eGFR levels.
Of the patients who began dialysis with eGFR p5, 6–10,
11–15, 16–20, and 420ml/min per 1.73m2, 21, 17, 8, 4, and
6%, respectively, received kidney transplants.
Relation between the level of eGFR at dialysis initiation
and mortality
When treated quantitatively, each 5-ml/min per 1.73m2
increase in the MDRD eGFR was associated with a 40%
increase in the overall mortality risk, and this reduced to half
after adjusting for age and gender (Table 3). Further
adjustment for comorbidities and nutritional status led to
an 8% increased risk, which remained statistically significant
after adjusting also for predialysis anemia care, initial
treatment conditions, and transplantation or wait listing.
Mortality hazard ratios (HRs) (95% confidence interval) at 3
months and 2 years were very similar. Patients with heart
failure had a higher fully adjusted mortality HR associated
with MDRD eGFR than those without, but the interaction
was on the borderline of significance (P¼ 0.06). The adjusted
HRs tended to differ according to initial dialysis condition,
but without significant interaction (P¼ 0.11). Other tested
interactions had P-values higher than 0.10.
Crude analysis by MDRD eGFR 5-percentile groups
showed linear rising relation with mortality (Figure 4). Fully
adjusted HRs for each group were all close to one, except for
the highest demi-decile (HR¼ 1.3 (1.1–1.6)). It was only of
borderline significance for the lowest one (HR¼ 0.8
(0.6–0.99)). It is noteworthy that these figures showed a
similar pattern for both hemo- and peritoneal dialysis
patients (data not shown). Subsidiary analysis excluding
these two extreme groups (o3.9 and 417ml/min per
1.73m2) led to a non-significant fully adjusted HR associated
with 5-ml/min per 1.73m2 increase in MDRD eGFR treated
quantitatively (1.03 (0.97–1.09)). When we used the Cock-
croft–Gault eGFR, the crude relation was U-shaped, and except
for the highest group, entirely explained by the covariates.
DISCUSSION
Recent concern about the potential detrimental effect of early
dialysis initiation was not confirmed in this study. We found
that eGFR at dialysis initiation was strongly related to
patient’s age, gender, and condition—those who started at
higher eGFR levels were older men with particularly high
percentage of diabetes (42%), heart failure (50%, of whom
31% with NYHA stage 3–4), and dysrhythmia (42%).
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Figure 1 |Distribution of Modification of Diet in Renal Disease
estimated glomerular filtration rate in ml/min per 1.73m2 at
start of dialysis.
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Furthermore, patients who began with an eGFR p5 or
415ml/min/1.73m2 were also more likely to have un-
planned dialysis than those who began with values within this
range. In contrast to other studies,12–14,16 we found that
patient characteristics from this large and unselected
population explained most of the inverse association of
eGFR with survival except for the 5% of the population with
the highest eGFR.
The rationale for commencing dialysis early is supported
by a number of observational and interventional studies,
reviewed by Canaud,18 which showed better survival in
patients who started dialysis with more preserved renal
function. These studies made clear that residual endogenous
renal function contributes to the adequacy of dialysis; reduces
interdialytic weight gain; and is associated with better
nutritional status, lower erythropoietin requirements, and
better outcomes.7,19,20 Although most guidelines provide
recommendations about GFR levels at which dialysis should
be initiated, they consistently underline the complexity of this
decision, in which patients and clinicians must weigh the
benefits, disadvantages, and risks of renal replacement
therapy. Evidence that several factors other than renal
function level have a role in the decision process comes
from the wide range of eGFR values at the start of dialysis
Table 1 | Patient characteristics according to MDRD eGFR at start of dialysis
MDRD eGFR (ml/min per 1.73m2)
Total (n) (11 685) p5 (1587) 6–10 (6683) 11–15 (2517) 16–20 (633) 420 (265) Pa
Mean age 67.0±15.3 60.6±16.7 66.1±15.1 71.1±13.9 73.5±13.0 71.8±14.4 o0.0001
Men 62.1 47.4 62.1 67.2 70.3 84.5 o0.0001
Primary renal disease o0.0001
Polycystic kidneys 6.9 6.7 8.5 4.7 0.8 1.1
Glomerulonephritis 12.2 15.8 13.0 9.4 7.3 8.3
Vascular or hypertensive nephropathy 25.5 18.7 25.0 28.5 34.0 32.1
Diabetic nephropathy 21.2 15.6 20.9 24.5 26.7 18.9
Other or unknown 34.2 43.3 32.6 32.9 31.3 39.6
Comorbidities and disabilities
Diabetes 35.8 26.3 34.1 42.6 47.2 41.9 o0.0001
Heart failure o0.0001
None 74.7 84.4 78.1 66.5 58.0 49.8
Stage I–II 14.4 9.7 13.3 18.4 21.0 15.9
Stage III–IV 8.9 4.7 6.7 12.8 18.0 31.3
Stage NA 2.0 1.2 2.0 2.4 3.0 3.0
Peripheral vascular disease o0.0001
None 77.6 88.5 79.0 71.8 65.9 60.8
Stage I–II 13.6 7.7 12.6 17.5 20.1 20.8
Stage III–IV 6.7 2.8 6.3 8.1 11.5 15.1
Stage NA 2.1 1.0 2.2 2.5 2.5 3.4
Coronary heart disease (CHD) o0.0001
History of myocardial infarction 11.2 5.9 10.4 14.7 16.4 20.4
CHD without myocardial infarction 14.2 8.0 13.6 17.8 21.2 18.1
Dysrhythmia 18.8 11.3 16.2 24.8 31.3 41.9 o0.0001
Malignancy 7.5 7.9 7.3 8.0 6.2 10.9 0.0014
Severe disabilityb 5.5 4.2 5.4 5.8 7.0 10.2 NS
Mobility 0.0042
Walk without help 59.6 66.9 62.2 53.1 46.5 43.0
Need assistance with mobility 10.8 8.8 10.1 12.3 14.2 16.6
Totally dependent for transfers 4.3 2.8 3.7 5.2 8.1 10.2
NA 25.4 21.5 24.0 29.4 31.3 30.2
Predialysis anemia care
Hemoglobin o11 g/dl 64.0 72.5 57.6 50.7 47.1 41.1 o0.0001
Predialysis ESA treatment 49.9 40.8 53.0 51.0 42.8 32.5 o0.0001
Nutritional status
Body mass index 25.5±5.3 25.8±5.8 25.6±5.2 25.3±5.4 24.9±5.4 24.5±4.9 0.03
Albuminemia (g/l) 33.6±6.5 33.0±6.2 33.9±6.4 33.5±6.6 32.9±7.0 32.6±6.7 0.0002
Initial dialysis condition o0.0001
Planned hemodialysis 57.1 44.8 61.6 56.2 50.2 43.4
Planned peritoneal dialysis 11.7 5.7 10.9 15.6 16.3 19.3
Unplanned dialysis 31.2 49.5 27.5 28.1 33.5 37.4
Abbreviations: eGFR, estimated glomerular filtration rate; ESA, erythropoietin-stimulating agent; MDRD, Modification of Diet in Renal Disease; NS, non-significant.
Mean±s.d. or %.
aP-value adjusted for age and gender.
bIncludes severe vision impairment, paraplegia, hemiplegia, and amputation.
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that we, like others,9 have observed, as well as from the 17%
of its variance explained here by patient characteristics. As in
other studies, we have found older age to be strongly
associated with early initiation of dialysis.2,12,13 Compared
with 2005 data from the USRDS, however, the percentage of
French patients starting with MDRD eGFR 410ml/min per
1.73m2 was about 10% lower in each age group.2 Men were
also more likely to start with higher eGFR levels than women,
probably in part because of their higher rate of cardiovascular
diseases. As shown in several other studies, patients started
peritoneal dialysis at eGFR levels higher than those started
with HD. The fact that 22–26% of those starting with
an eGFR 4 15ml/min per 1.73m2 had impaired mobility
clearly indicates sicker patients. Interestingly, not only did
patients with very low eGFR begin dialysis on an emergency
basis, but so did more than a third of those with eGFR
415ml/min per 1.73m2. The reliability of this variable was
recently assessed showing that 83% of the patients labeled
with unplanned dialysis were never scheduled for a first
dialysis session, and that 80% of them began dialysis within
48 h after the decision was made.21 Starting dialysis at a high
eGFR level thus does not necessarily reflect a ‘timely’ start. It
is indeed clear from this study as well as from others22 that
these patients have more comorbidities, particularly severe
heart failure. As discussed in the last KDOQI on Dialysis
Adequacy,3 dialysis initiation at high eGFR in these patients is
based on experience and the hope or impression that dialysis
therapy may alleviate or attenuate symptoms. The fact that
this group started more often with more than three HD
sessions per week is further evidence that these high-eGFR
patients did not start in a timely progressive manner at a low
dialysis dose. Whether this practice, which concerned 14
patients only in this study, is beneficial would need to be
evaluated in a larger sample.
Our study is comparable to that of Beddhu et al.,12 Kazmi
et al.,13 and Stel et al.16 with respect to study design and
population, as well as for both mean or median MDRD eGFR
at start: the mean was 8.4 in the study of Kazmi et al.13 and
8.6 in that of Stel et al.16 versus 8.8ml/min per 1.73m2 in
ours, and the median was 7.5 in the study of Bedhhu et al.12
and 7.7 in that of Stel et al.16 versus 7.9ml/min per 1.73m2 in
our study. Beddhu et al.12 found HRs similar to that in our
study for each 5-ml/min per 1.73m2 increase in MDRD
eGFR: crude HR: 1.36 (1.28–1.44) and fully adjusted HR: 1.14
(1.06–1.22) versus 1.40 (1.36–1.45) and 1.09 (1.05–1.13) in
our study. Kazmi et al.13 and Stel et al.16 also observed quite
similar adjusted HRs for each 5-ml/min/1.73m2 eGFR
increase, being 1.17 (1.16–1.18) and 1.15 (1.10–1.15),
respectively. However, our study showed that when eGFR
was treated semi-quantitatively the statistical significance of
the fully adjusted HR resulted mostly from the combination
of a very low mortality risk associated with the lowest 5-
percentile group of the eGFR distribution and an elevated
risk with the highest demi-decile; the mortality risk
Table 2 |Mean weekly number and duration of hemodialysis sessions according to MDRD eGFR
MDRD eGFR (ml/min per 1.73m2)
Total (n) (9804) p5 (1411) 5–10 (5646) 10–15 (2040) 15–20 (507) 420 (200) Pa
Mean duration of HD sessions (h/week) 11.3±2.2 11.7±1.8 11.4±2.2 11.2±2.4 11.1±2.5 11.3±2.8 o0.0001
Weekly number of sessions (%) o0.0001
1–2 9 5 9 11 11 7
3 90 94 90 88 86 86
43 1 1 1 1 2 7
Abbreviations: eGFR, estimated glomerular filtration rate; HD, hemodialysis; MDRD, Modification of Diet in Renal Disease.
aP-value adjusted for age and gender.
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Figure 2 |Proportion of patients starting dialysis at an
estimated GFR higher than 10ml/min per 1.73m2 by age
group.
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Figure 3 |Kaplan–Meier survival curves according to MDRD
eGFR in ml/min per 1.73m2 at start of dialysis.
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associated with all other 5-percentile groups did not differ
significantly from the reference. This means that, except at
the extreme eGFR values, the covariates we studied entirely
explained the inverse crude association observed with
mortality. It is noteworthy that once excluding these two
extreme groups, the adjusted HR associated with eGFR
treated as a continuous variable was no longer statistically
significant. Patients starting dialysis with very low eGFR were
typically young, had few comorbidities, and had a high rate
of early transplantation. This probably reflects common
clinical practices aimed at maintaining young patients free of
dialysis as long as possible in the hope for a preemptive
transplantation. Such practices are likely to select a much
healthier subgroup at particularly low mortality risk. In
contrast, the significantly higher mortality risk in patients
starting HD at very high eGFR levels may result from either
residual confounding from unrecorded risk factors, measure-
ment error, indication bias, or a detrimental effect of dialysis.
All four hypotheses are plausible. Despite the number and
quality of collected comorbidities, which together reduced
the mortality HR by 25% in addition to the 50% reduction
already due to age and gender, we cannot rule out the
potential effect of other unknown factors such as lack of
treatment compliance or difficulty in the management of
multiple and severe conditions or any other post-initiation
issues. Beddhu et al.,23 showed that BMI was not a good
measure of the degree of malnutrition, and that MDRD eGFR
may overestimate true GFR in patients with advanced kidney
failure, low muscle mass, and low creatinine generation.
Some of those labeled as early starters may have actually
started late as a result of spuriously high eGFR due to low
serum creatinine relative to true GFR. Adjusting for BMI and
serum albumin may therefore be insufficient to account for
the potential confounding effect of malnutrition in the
studied association. The extremely high rate of heart failure
among patients in this highest demi-decile of the eGFR
distribution may argue for indication bias. Conversely, early
dialysis initiation may accelerate residual renal function loss
and therefore compromise other metabolic functions, which
are shown to have a strong impact on outcome.2,9,18 Patients
are also exposed earlier to well-known adverse effects of
dialysis, including infections, hemodynamic stress, and
membrane bioincompatibility.
The major strengths of this analysis include the study
power, which allowed detailed analysis by eGFR level, the
number, and the relevance of recorded variables, as well as
the unselected nature of the population in comparison with
other studies.10,11,15 Our findings, however, should be
interpreted in light of the following limitations. First, this
is an observational study and patients were not randomly
allocated to eGFR level at dialysis initiation. Therefore,
despite careful adjustments for patient conditions, confound-
ing by indication was not controlled as it would be in a
randomized trial. Furthermore, because this study was based
only on dialysis patients, survival bias cannot be ruled out to
explain, for example, the apparent lower risk for death in
patients starting at very low MDRD eGFR levels. Some
patients reaching such low levels might have died before
starting renal replacement therapy, whereas others in better
condition may have survived until treatment. It should not be
hastily concluded from this study that patients can start
dialysis with eGFR below the international consensus value of
5ml/min per 1.73m2. It is nonetheless worth pointing out
that about one out of six of the overall French dialysis
population were able to do so, likely because of their younger
age and a much healthier profile.
Second, GFR was estimated and not measured. The
MDRD equation has been shown to perform better than the
Cockcroft and Gault equation at low GFR levels in diverse
populations.24–26 Although the latter is in the process of
Table 3 | HRs of overall, 3-month, and 2-year mortality associated with 5-ml/min per 1.73m2 increase of MDRD eGFR, and of
overall mortality by initial dialysis condition and heart failure status
Model-1: crude
Model-2: adjusted for
age and gender
Model-3: 2+ comorbiditiesa,
mobility, and nutritional statusb
Model-4: 3+ predialysis anemia carec,
initial treatment condition,
wait listing, or transplantation
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Overall 1.40 (1.36–1.45) 1.20 (1.16–1.25) 1.08 (1.04–1.12) 1.09 (1.05–1.13)
Three months 1.41 (1.31–1.51) 1.22 (1.13–1.32) 1.07 (0.99–1.15) 1.09 (1.01–1.17)
Two years 1.41 (1.36–1.46) 1.21 (1.17–1.26) 1.09 (1.04–1.13) 1.09 (1.05–1.14)
Initial dialysis condition
Planned HD 1.49 (1.41–1.57) 1.26 (1.19–1.34) 1.13 (1.07–1.20) 1.12 (1.06–1.19)
Planned PD 1.38 (1.26–1.51) 1.16 (1.05–1.29) 0.98 (0.88–1.10) 1.00 (0.89–1.12)
Unplanned 1.35 (1.29–1.41) 1.20 (1.13–1.26) 1.09 (1.03–1.15) 1.08 (1.03–1.15)
Heart failure
Yes 1.27 (1.21–1.34) 1.21 (1.14–1.28) 1.12 (1.06–1.18) 1.11 (1.05–1.18)
No 1.34 (1.28–1.41) 1.12 (1.07–1.18) 1.05 (1.00–1.11) 1.06 (1.01–1.12)
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; HD, hemodialysis; HR, hazard ratio; MDRD, Modification of Diet in Renal Disease;
PD, peritoneal dialysis.
aComorbidities include diabetes, heart failure, dysrhythmia, peripheral vascular disease, coronary heart disease, malignancy, and severe disability.
bNutritional status includes body mass index and albuminemia.
cPredialysis anemia care includes hemoglobin and pre-dialysis erythropoietin-stimulating agent treatment.
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replacement by the former, it was still the equation
recommended by French health authorities during the study
period and the one chosen to randomize patients in the on-
going Initiating Dialysis Early and Late (IDEAL) trial.27 It is
therefore important to point out that the pattern of the crude
association of eGFR with mortality differed substantially
according to equation. Explanation for divergent findings was
related to weight. When using the Cockcroft and Gault equation,
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Figure 4 |HRs of mortality by 5-percentile of the GFR distribution in ml/min per 1.73m2, estimated with the MDRD and
Cockcroft–Gault equations. Model-1: crude HRs; Model-2: HRs adjusted for age and gender; Model-3: HRs also adjusted for diabetes, heart
failure, dysrhythmia, peripheral vascular disease, coronary heart disease, malignancy, severe disability, mobility, and nutritional status;
Model-4: HRs further adjusted for predialysis anemia care, initial treatment condition, and access to waiting list or transplantation.
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obese patients tend to have higher eGFR and thin patients, lower
eGFR for a same level of creatinine.25 Therefore, because the
relation between BMI and mortality is U-shaped, both crude and
age- and gender-adjusted HRs also reflect this association. After
adjusting for age, gender, and BMI, the pattern of the association
was very similar using either equation.
Third, lead-time bias should be taken into account in the
interpretation of the results. As described in the NECOSAD
study,10 this bias may result in falsely prolonged survival simply
because patients are started at an earlier stage of the disease. In
the absence of any effect from early dialysis start, one would
therefore expect some negative association between increasing
eGFR and mortality, which we did not observe. Consequently, a
detrimental effect of early dialysis initiation may be under-
estimated in this study. Finally, 27% of the patients had missing
MDRD eGFR values. These patients, however, did not differ
significantly regarding age from those with available data and
only slightly for those factors most strongly associated with
baseline eGFR, such as gender, heart failure, and diabetes. In
the same way, the 1516 patients (11%) with eGFR but missing
covariates did not significantly differ from those studied with
respect to eGFR distribution at initiation as well as the crude
association between eGFR and mortality (data not shown). We
thus believe that our findings can be fairly generalized to the
entire French population on dialysis.
We conclude that patients’ age and comorbidities are strongly
related to eGFR at dialysis initiation. In this observational study,
these factors explained most of the paradoxical crude association
between increasing eGFR and mortality. Considering that early
start of dialysis is costly and has major consequences in the
personal life of patients, strong evidence is required to justify
early start. The ongoing IDEAL trial should provide further
evidence regarding the effect that eGFR at initiation has on
survival.27 Our findings, however, emphasize the predominant
role of patient condition over eGFR in the decision to initiate
dialysis and subsequently on the outcome. Further research is
needed to assess whether starting at higher eGFR affects overall
quality of life and morbidity.
MATERIALS AND METHODS
Population
The REIN Registry includes all ESRD patients on renal replacement
therapy—either dialysis or transplantation—treated in France.
Patients with acute kidney failure are excluded, that is, those who
recover all or some renal function within 45 days or who die before
45 days and are diagnosed with acute kidney failure by experts. The
registry began in 2002 and has grown progressively to include the
entire country in 2009. The details of its methods and quality
control are described elsewhere.28 Between 2002 and 2006, a total of
18,891 patients aged over 16 years started dialysis in 16 of 20 regions
that together cover 79% of the French population. From these, we
excluded 387 patients with preemptive grafts and 232 who recovered
renal function within 6 months of dialysis initiation.
Information
Baseline information included age, gender, primary renal disease,
BMI, as well as serum albumin, serum creatinine, and hemoglobin
levels and use of ESA. In this analysis, we studied the following
comorbidities: diabetes, hypertension, congestive heart failure
(NYCA stages I–IV), coronary heart disease with or without a
history of myocardial infarction, dysrhythmia, stroke or transient
ischemic attack, peripheral vascular disease (Leriche classification
stages I–IV), chronic respiratory disease, malignancy, liver disease
(cirrhosis or viral hepatitis), HIV infection or AIDS, and smoking.
We also considered mobility status and severe disabilities that may
affect patient independence, such as severely impaired vision,
amputation, hemiplegia, and paraplegia. Initial dialysis conditions
were classified as planned HD, planned peritoneal dialysis, or
unplanned dialysis, defined as any first dialysis begun on an
emergency basis, that is, in life-threatening circumstances requiring
dialysis within 24 h. We also analyzed dialysis dose related to eGFR,
on the basis of the duration and number of weekly HD sessions.
Patients with either creatinine value o200mmol/l or MDRD
(Modification of Diet in Renal Disease study) eGFR 460ml/min
per 1.73m2 (n¼ 136) or with missing creatinine (n¼ 4935) were
excluded from the analysis. We used MDRD eGFR24 throughout the
analysis, but tested the consistency of our results with the
Cockcroft–Gault eGFR, which was used to randomize patients in
the IDEAL study.27
One of the authors (M. Labeeuw) conducted a validation study
of the files of 90 of the 285 patients with MDRD eGFR420ml/min
per 1.73m2, to assess the potential for misclassification in these high
values. Seven of them (8%) resulted from coding errors and were
corrected, one was collected more than 6 months before starting
dialysis and was changed to missing value, and another identified a
patient with acute kidney failure who was excluded from the
database. All the others (90%) proved to be correct. Besides
creatinine, the only variables with more than 5% missing data were
hemoglobin, albuminemia, BMI, and mobility status. A missing
category was added in the multivariate analyses for these four
variables. For the others, missing values resulted in the exclusion of
1516 patients, leaving a total of 11,685 patients for this analysis.
Deaths and transplantations were registered on occurrence from
the first day of dialysis through the study end-point on 31 December
2007.
Statistical methods
Baseline characteristics were studied by the class of MDRD eGFR
(p5, 5–10, 10–15, 15–20, and 420ml/min per 1.73m2) and tested
for significant associations after adjusting for age and gender. The
percentage of eGFR variance explained by these characteristics was
estimated with multivariate analysis, with eGFR treated as
continuous. To assess the potential for bias due to missing creatinine
values, we compared the characteristics of patients with and without
these data. The two groups did not significantly differ regarding age,
but those included in the analysis were more often men (62 versus
60%, P¼ 0.02), less likely to have diabetes (36 versus 38%, age- and
gender-adjusted P¼ 0.047) or heart failure (25 versus 28%, adjusted
Po0.001) and more likely to have started with unplanned dialysis
(31 versus 26%, adjusted Po0.001).
The Kaplan–Meier method was used to estimate patient survival
by eGFR class. Four Cox proportional hazard models were then fit to
analyze the relations between eGFR and overall mortality, with
sequential adjustment for explanatory variables. Model-1 was crude;
Model-2 was adjusted for age and gender; Model-3 added the
comorbid conditions and nutritional status indicators significantly
associated with eGFR in the first step; and Model-4 also adjusted for
predialysis anemia care, initial treatment conditions, wait-listing,
and transplantation. In these models, MDRD eGFR was treated both
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quantitatively, by 5ml/min per 1.73m2, to compare with
others,12,13,16 and semi-quantitatively, by 5-percentile groups of
the distribution (that is, by demi-deciles), with the fifteenth group,
including values around 10 (9.9–10.6) ml/min per 1.73m2, as the
reference category. Interactions between patient or treatment
conditions and eGFR were systematically tested. Models 1–4 were
applied for the overall population as well as by treatment modality
and heart failure status. To assess whether eGFR had a stronger
impact on early versus late mortality, we studied HRs at 3 months
and at 2 years. Finally, we estimated crude and adjusted HRs with
the Cockcroft–Gault eGFR, by 5-percentile groups, with the eleventh
group, including values around 10 (9.6–10.1ml per min/1.73m2), as
the reference.
The Strata option from SAS PROC PHREG was used to account
for the region effect. By using this option, risks were estimated
separately within each region and pooled across all regions. The
proportional hazards assumption was evaluated by analyzing the
scaled Schoenfeld residuals. Significance between the four nested
Cox models was tested with the log-likelihood ratio. A P-value of
0.05 was the level for statistical significance in all analyses. SAS
software, version 9 (SAS Institute, Cary, NC, USA) was used to
perform the analyses.
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